Last reviewed · How we verify
NCT06886919: IC19 CAR-T
Clinical Study Evaluating the Safety and Efficacy of IC19 CAR-T Cell Therapy for Refractory Systemic Lupus Erythematosus
EARLY_PHASE1 trial testing Engineering of chimeric antigen receptors targeting CD19 in allogeneic T cells in Difficult to Treat Systemic Lupus Erythematosus in 6 participants. Not yet recruiting.
30 September 2025
Quick facts
| Lead sponsor | Beijing Immunochina Medical Science & Technology Co., Ltd. |
|---|---|
| Phase | EARLY_PHASE1 |
| Status | Not yet recruiting |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | sequential |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 6 |
| Start date | 31 March 2025 |
| Primary completion | 30 September 2025 |
| Estimated completion | 30 May 2026 |
Drugs / interventions tested
- Engineering of chimeric antigen receptors targeting CD19 in allogeneic T cells — full drug profile →
Conditions studied
- Difficult to Treat Systemic Lupus Erythematosus — all drugs for Difficult to Treat Systemic Lupus Erythematosus →
Sponsor
Beijing Immunochina Medical Science & Technology Co., Ltd. — full company profile →
Who can join
Adults 18 to 70, any sex, with Difficult to Treat Systemic Lupus Erythematosus. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study is an open label, single arm exploratory clinical trial of IC19 CAR-T cell therapy for refractory systemic lupus erythematosus. Patients who are still in an active state after systemic treatment using the standard treatment regimen specified in the treatment guidelines were selected to receive IC19 CAR-T cell single pulse infusion therapy.
Publications & conference data
2 peer-reviewed publications reference this trial (live from Europe PMC):
-
Roads and detours for CAR T cell therapy in autoimmune diseases.
Avouac J, Barzel A, Caiati D, Davis RS, et al · · 2026 · cited 1× · PMID 41588112 · DOI 10.1038/s41573-025-01349-4 -
Prospects for Development and Commercialisation of Allogeneic CAR-Based Therapies for Autoimmune Disease.
Osborne M, Maher J. · · 2025 · PMID 41463563 · DOI 10.3390/biology14121790
Verify or expand the search:
- PubMed search for NCT06886919
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other Beijing Immunochina Medical Science & Technology Co., Ltd. trials
Trials by the same sponsor.
- NCT07406984 — Clinical Study of IM96 CAR-T Cell Therapy in Patients With Advanced Adenocarcinoma of Gastric/Esophagogastric Junction · Phase 1 · not yet recruiting
- NCT06852573 — Clinical Study of ZM001 Injection in the Treatment of Refractory Systemic Lupus Erythematosus · Phase 1 · not yet recruiting
- NCT06718738 — Clinical Study of IM96 CAR-T Cell Therapy in Patients With Advanced Colorectal Cancer · Phase 1 · recruiting
- NCT06690359 — IM19 CAR-T Cell Therapy for IgA Nephropathy Patients and Membranous Nephropathy Patients · EARLY_PHASE1 · not yet recruiting
- NCT06691308 — WL276 CAR-T Cell Therapy for CD276 Positive Recurrent or Progressive Glioblastoma Patients · EARLY_PHASE1 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06886919 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Beijing Immunochina Medical Science & Technology Co., Ltd.
- Last refreshed: 24 March 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06886919.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing